Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ: KRYS )

160.49 +1.97 (+1.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Krystal Biotech Inc. (NASDAQ: KRYS) Highlighted for Surprising Price Action
Via Investor Brand Network
Analyst Expectations for Krystal Biotech's Future
Via Benzinga
FDA Approves First Redosable Gene Therapy, Krystal Biotech's Treatment For Skin Blistering Disorder
The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for the treatment of patients six months of age or older with dystrophic  
Via Benzinga
NVIDIA To Rally Around 22%? Here Are 10 Other Analyst Forecasts For Monday
Needham cut the price target for Wix.com Ltd. (NASDAQ: WIX) from $125 to $120. Needham analyst Bernie McTernan maintained a Buy rating. Wix.com shares dropped 3.2% to close at $78.09 on Friday. 
Via Benzinga
Expert Ratings for Krystal Biotech
Via Benzinga
Dentsply Sirona, Chico's FAS, Kontoor Brands And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping more than 150 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Krystal Biotech Epidermolysis Bullosa Study Data Published In New England Journal Of Medicine
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023
Via Benzinga
2 Risky Stocks That Could Soar in 2023
These "exciting" companies aren't for everyone. 
Via The Motley Fool
Krystal Biotech's Subsidiary Posts Durability Data For Fine Line, Wrinkles
Via Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period. 
Via Benzinga
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
Biotech is one of the safest, recession-proof sectors on the market. It's why we're going after the hottest biotech stocks in the New Year. 
Via InvestorPlace
SolarEdge To Rally 54%? Plus This Analyst Predicts $1,335 For Mettler-Toledo International
Goldman Sachs raised the price target on Mettler-Toledo International Inc. (NYSE: MTD) from $1,120 to $1,335. Goldman Sachs analyst Matthew Sykes upgraded the stock from Sell to Neutral. Mettler-Toledo... 
Via Benzinga
Cigna To $335? Plus This Analyst Slashes PT On Six Flags Entertainment By 25%
  SVB Leerink raised the price target on Cigna Corporation (NYSE: CI) from $305 to $335. Cigna shares rose 0.7% to close at $324.37 on Monday. 
Via Benzinga
Recap: Krystal Biotech Q3 Earnings
Krystal Biotech (NASDAQ:KRYS) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: Krystal Biotech Q4 Earnings
Krystal Biotech (NASDAQ:KRYS) reported its Q4 earnings results on Monday, February 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades 
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
FDA Accepts Krystal Biotech's Filing For Genetic Skin Disorder Candidate Under Priority Review
The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ: KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with... 
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Krystal Biotech Gets FDA Nod For Initial-Stage Lung Infection Study
The United States Food and Drug Administration (FDA) has accepted Krystal Biotech’ (NASDAQ: KRYS) Investigational New Drug (IND) application to evaluate KB407 in a clinical trial for cystic fibrosis... 
Via Benzinga
Krystal Biotech Files To Seek Approval For Skin Disease Candidate
Krystal Biotech, Inc. (NASDAQ: KRYS) submits biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of B-VEC (beremagene geperpavec) in the treatment of... 
Via Benzinga
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade
On Thursday, Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from to 93, up 88 a day ago. 
Via Investor's Business Daily
BofA Bullish On This Gene Therapy Biotech Transitioning Into A Commercial Enterprise
Krystal Biotech Inc (NASDAQ:KRYS) shares have po... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022
Upgrades Canaccord Genuity upgraded the previous rating for Fortuna Silver Mines Inc (NYSE: 
Via Benzinga
Why Krystal Biotech's Shares Rose More Than 77% This Week
The company had a positive phase 3 trial for its therapy to fight a rare genetic skin disease. 
Via The Motley Fool
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.